Understanding the role of human variation in vaccine adverse events: The clinical immunization safety assessment network

Pediatrics

Volumn 127, Issue SUPPL. 1, 2011, Pages

  LaRussa, Philip S ^a   Edwards, Kathryn M ^b   Dekker, Cornelia L ^c   Klein, Nicola P ^d   Halsey, Neal A ^e,f   Marchant, Colin ^g   Baxter, Roger ^d   Engler, Renata J M ^h   Kissner, Jennifer ^b   Slade, Barbara A ⁱ  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d KAISER PERMANENTE   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g BOSTON MEDICAL CENTER   (United States)

^h WALTER REED ARMY MEDICAL CENTER   (United States)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Adverse events following immunization; CISA network; Vaccine safety

Indexed keywords

CHICKENPOX VACCINE; INFLUENZA VACCINE; SMALLPOX VACCINE; VACCINE;

ALGORITHM; CHICKENPOX; DRUG FEVER; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED MEDICINE; GENETIC POLYMORPHISM; GENETIC RISK; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA A (H1N1); INFORMATION PROCESSING; INTERDISCIPLINARY COMMUNICATION; MYELITIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEIZURE; SMALLPOX; TELEPHONE; UNSPECIFIED SIDE EFFECT; VACCINATION; VACCINATION REACTION;

ACADEMIC MEDICAL CENTERS; ADVERSE DRUG REACTION REPORTING SYSTEMS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); COMPREHENSION; DRUG TOXICITY; FEMALE; HEALTH EDUCATION; HUMANS; IMMUNIZATION; INFORMATION SERVICES; MALE; RISK ASSESSMENT; ROLE; SAFETY MANAGEMENT; UNITED STATES; VACCINATION; VACCINES;

EID: 79952482931     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-1722J     Document Type: Review

References (31)

1. Chen RT, Glasser, JW, Rhodes PH. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics. 1997;99(6):765-773 (Pubitemid 27231345)
2. Wood RA, Berger M, Dreskin SC, et al; Hypersensitivity Working Group of the Clinical Immunization Safety Assessment (CISA) Network. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics. 2008;122(3). Available at: www.pediatrics.org/cgi/content/full/122/ 3/e771
3. Wood R, Setse R, Halsey N; Clinical Immunization Safety Assessment (CISA) Network Hypersensitivity Working Group. Irritant skin test reactions to common vaccines. J Allergy Clin Immunol. 2007;120(2):478-481
4. Halsey N. Anthrax vaccine and causality assessment from individual case reports. Pharmacoepidemiol Drug Saf. 2002;11(3):185-187 (Pubitemid 34537523)
5. Halsey N. The science of evaluation of adverse effects associated with vaccination. Semin Pediatr Infect Dis. 2002;13(3):205-214
6. Muralles A, Ray P, Black S, et al. Active telephone surveillance to evaluate adverse events among civilian smallpox vaccine recipients. Vaccine. 2006;24(4):476-484 (Pubitemid 41832551)
7. Rosenberg M, Sparks R, McMahon A, Iskander J, Campbell JD, Edwards KM. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age. Vaccine. 2009;27(32):4278-4283
8. Qiang Y, Krishnan C, Kerr D, Setse R, Quigg M, Halsey N. Idiopathic acute transverse myelitis: comparison of patients with vs. without receipt of a vaccine within 30 days prior to onset. Presented at: 24th International Conference for Pharmacoepidemiology and Therapeutic risk Management; August 17-20, 2008; Copenhagen, Denmark
9. Klein N, Fireman B, Enright A, Ray P, Black S, Dekker C. A role for genetics in the immune response to the varicella vaccine. Pediatr Infect Dis J. 2007;26(4):300-305 (Pubitemid 46596652)
10. Klein N, Edwards K, Sparks R, Dekker C; Clinical Immunization Safety Assessment (CISA) Network. Recurrent sterile abscesses following immunization: a possible association with aluminum adjuvant. BMJ Case Rep. 2009;
11. Ball R, Halsey N, Braun MM, et al; VAERS Working Group. Development of case definitions for acute encephalopathy, encephalitis, and multiple sclerosis reports to the Vaccine Adverse Event Reporting System. J Clin Epidemiol. 2002;55(8):819-824
12. Rothstein E, Kohl KS, Ball L, et al; Brighton Collaboration Local Reaction Working Group. Nodule at injection site as an adverse event following immunization case definition and guidelines for data collection, analysis, and presentation. Vaccine. 2004;22(5-6):575-585 (Pubitemid 38114884)
13. Bonhoeffer J, Menkes J, Gold MS, et al; Brighton Collaboration Seizure Working Group. Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine. 2004;22(5-6):557-562 (Pubitemid 38114881)
14. Graham PL, LaRussa PS, Kohl KS; Brighton Collaboration Vaccinia Virus Adverse Event Working Group for Robust Take. Robust take following exposure to vaccinia virus: case definition and guidelines of data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25(31):5763-5770 (Pubitemid 47043214)
15. Beigel J, Kohl K, Brinley F, et al; Brighton Collaboration Vaccinia Virus Vaccine Adverse Event Working Group for Generalized Vaccinia. Generalized vaccinia as an adverse event following exposure to vaccinia virus: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25(31):5745-5753 (Pubitemid 47049768)
16. Nell P, Kohl P, Graham P, et al; Brighton Collaboration Vaccinia Virus Vaccine Adverse Event Working Group for Eczema Vaccinatum. Eczema vaccinatum as an adverse event following exposure to vaccinia virus: case definition and guidelines of data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25(31):5725-5734 (Pubitemid 47049767)
17. Nell P, Kohl K, Graham P, et al; Brighton Collaboration Vaccinia Virus Vaccine Adverse Event Working Group for Progressive Vaccinia. Progressive vaccinia as an adverse event following exposure to vaccinia virus: case definition and guidelines of data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25(31):5735-5744 (Pubitemid 47049770)
18. Wenger P, Oleske J, Kohl K, et al; Brighton Collaboration Vaccinia Virus Adverse Event Working Group for Inadvertent Inoculation. Inadvertent inoculation as an adverse event following exposure to vaccinia virus: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25(31):5754-5762 (Pubitemid 47049769)
19. Kohl KS, Magnus M, Ball R, Halsey N, Shadomy S, Farley TA. Applicability, reliability, sensitivity, and specificity of six Brighton Collaboration standardized case definitions for adverse events following immunization. Vaccine. 2008;26(50):6349-6360
20. Slingluff M, Klote M, Hemann B, et al. A pilot study: trivalent inactivated influenza vaccine (TIV) and myopericarditis [abstract]. J Allergy Clin Immunol. 2007;119(1 suppl):S96. Abstract 376
21. Klein NP, Kissner J, Aguirre A, et al. Differential maternal responses to a newly developed vaccine information pamphlet. Vaccine. 2009;28(2):323-328
22. Casey C, Campbell S, Iskander J, et al. Clinical assessment of adverse events following immunization (AEFIs): a converging new international paradigm? Pharmacoepidemiol Drug Saf. 2004;13(S1):S13-S14
23. Klein NP, Massolo M, Greene J, Dekker C, Black S, Escobar G; Vaccine Safety Datalink. Risk factors for developing apnea following immunization in the NICU. Pediatrics. 2008;121(3):463-469
24. Klein NP, Gans H, Sung P, et al. Preterm infants' T cell responses to inactivated poliovirus vaccine. J Infect Dis. 2010;201(2):214-222
25. Rennels M, Black S, Woo E, Campbell S, Edwards K. Safety of a fifth dose of diphtheria and tetanus toxoid and acellular pertussis vaccine in children experiencing extensive, local reactions to the fourth dose. Pediatr Infect Dis J. 2008;27(5):464-465
26. Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26(48):6077-6082
27. Rollison D, Helzlsouer K, Halsey N, Shah K, Viscidi R. Markers of past infection with simian virus 40 (SV40) and risk of incident non-Hodgkin lymphoma in a Maryland cohort. Cancer Epidemiol Biomarkers Prev. 2005;14(6):1448-1452 (Pubitemid 40807344)
28. Durbin AP, Setse R, Omer SB, et al. Monitoring adverse events following yellow fever vaccination using an integrated telephone and Internet-based system. Vaccine. 2009;27(44):6143-6147
29. Sundberg J, Silva K, Edwards K, Black B, Jenson A, King L. Failure to induce alopecia areata in C3H/HeJ mice with exogenous interferon gamma. J Exp Anim Sci. 2007;43(4):265-270 (Pubitemid 46179201)
30. Klein NP, Aukes L, Lee J, et al. Evaluation of immunization rates and safety among children with inborn errors of metabolism. Pediatrics. 2011; In press
31. Schlegel C, Edwards KM, Morgan T, Welch-Burke T, Lee HS, Summar M; Urea Cycle Consortium. Hyperammonemic events are not associated with a 21 day post-vaccination window in 90 children with urea cycle disorders (UCDs). Presented at: 11th International Congress of Inborn Errors of Metabolism; August 29-September 2, 2009; San Diego, CA